AI Automated Translation.

Font Size

Share

Ginkgo biloba extract found to improve walking ability in patients with intermittent claudication

Ginkgo biloba extract found to improve walking ability in patients with intermittent claudication

Seoul St. Mary's Hospital
Seoul St. Mary's Hospital

A new study has found that ginkgo biloba extract can improve walking ability in patients with intermittent claudication, a condition that causes pain and discomfort in the lower-body muscles while walking.

A research team led by Professors Park Soon-cheol and Oh Haeng-jin of Seoul St. Mary's Hospital announced the findings on Nov. 19 following a meta-analysis of the efficacy and safety of ginkgo biloba extract in treating intermittent claudication, a common symptom of peripheral artery disease.

The study combined findings from clinical trials conducted in South Korea and abroad and was published in the international journal Journal of Clinical Medicine.

The research team systematically reviewed clinical trials related to ginkgo leaf extract for intermittent claudication in patients with peripheral artery disease through major academic databases.

By integrating 14 randomized, double-blind, placebo-controlled clinical trials (involving a total of 893 patients) that compared ginkgo leaf extract with a placebo, they evaluated the latest clinical evidence on the efficacy and safety of ginkgo leaf extract.

Peripheral artery disease is a condition in which blood flow decreases due to atherosclerotic occlusion of the lower limb arteries. Intermittent claudication, its representative symptom, is characterized by pain in the calves, thighs, or buttocks during walking that relieves upon rest. Treatment efficacy is generally evaluated using walking ability indicators such as maximum walking distance.

Considering that walking distance measurement conditions varied across studies, the research team analyzed efficacy based on energy expenditure (kcal) during walking.

As a result, the ginkgo leaf extract group showed a statistically significant improvement in maximum walking distance (ACD) compared to the placebo group (MD 3.50 kcal, p=0.049). This corresponds to an improvement of approximately 60 meters based on actual walking distance.

A more pronounced improvement effect was confirmed in the 24th-week treatment group. In seven studies analyzing 24 weeks of treatment, maximum walking distance improved by 4.67 kcal compared to the placebo group (p<0.001). This corresponds to an improvement effect of approximately 81 meters based on actual walking distance.

The research team analyzed that such results appeared due to the long-term accumulation of ginkgo leaf extract's effects in improving blood flow, as well as its antioxidant and microcirculation-improving properties.

In safety assessments, ginkgo leaf extract showed a safety profile similar to the placebo group. No new safety issues were identified.

Recent domestic multi-institutional studies also indicated that the incidence of adverse events was at a level similar to the placebo group, with no reports of serious drug adverse reactions.

This study is a meta-analysis that additionally incorporates the latest clinical trial results published since the 2013 Cochrane Review (systematic literature review).

By including domestic multi-institutional clinical trial results, it more broadly evaluated the clinical evidence regarding ginkgo leaf extract's effect on improving walking distance and its safety.

Professor Oh Haeng-jin said, "Ginkgo leaf extract has been used in patients with intermittent claudication based on mechanisms such as peripheral blood flow improvement and antioxidant action."

He added, "This study is significant because, by analyzing clinical trial results added since the existing Cochrane Review, it reconfirmed the previously observed walking distance improvement effect in a larger patient population and further solidified its clinical evidence."

"This article was translated using AI and may differ slightly from the original."